Syndax Pharmaceuticals (NASDAQ: SNDX) and Cesca Therapeutics (NASDAQ:KOOL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitabiliy and dividends.

Earnings and Valuation

This table compares Syndax Pharmaceuticals and Cesca Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Syndax Pharmaceuticals $1.22 million 199.61 -$48.05 million ($2.61) -5.11
Cesca Therapeutics $14.00 million 2.55 -$6.73 million ($5.28) -0.68

Cesca Therapeutics has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Cesca Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Syndax Pharmaceuticals and Cesca Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syndax Pharmaceuticals 0 0 10 0 3.00
Cesca Therapeutics 0 1 0 0 2.00

Syndax Pharmaceuticals presently has a consensus target price of $26.00, suggesting a potential upside of 94.90%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Cesca Therapeutics.

Volatility & Risk

Syndax Pharmaceuticals has a beta of 5.07, suggesting that its stock price is 407% more volatile than the S&P 500. Comparatively, Cesca Therapeutics has a beta of -0.72, suggesting that its stock price is 172% less volatile than the S&P 500.

Insider and Institutional Ownership

53.6% of Syndax Pharmaceuticals shares are held by institutional investors. Comparatively, 2.4% of Cesca Therapeutics shares are held by institutional investors. 24.1% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 3.9% of Cesca Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Syndax Pharmaceuticals and Cesca Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Syndax Pharmaceuticals -3,861.72% -52.82% -41.67%
Cesca Therapeutics -225.90% -33.56% -23.23%

Summary

Syndax Pharmaceuticals beats Cesca Therapeutics on 8 of the 13 factors compared between the two stocks.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company‚Äôs product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

About Cesca Therapeutics

Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.

Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.